TICKERNERD
Menu
ZYMEZYMEHealthcare · Biotechnology

ZYME Stock Forecast: Zymeworks, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$25
−4.79% on the day

The 14 Wall Street analysts covering Zymeworks, Inc. hold a median 12-month price target of $38 — +50.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 63 of 100 as at 8 Oct 2026 — in the upper half.

Market cap
$1.8B
Ticker Nerd rank
63 / 100
Median analyst target
$38
Analysts covering
14
Revenue$4.6M−90.6% y/y
Operating income−$42.1M
Net income−$45.0M
Free cash flow−$31.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.7%
1M
−10.1%
YTD
−4.1%
1Y
+51.4%
From 52W high
−18.6%
From 52W low
+53.5%
$16
$31
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ZYME stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Zymeworks, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
63 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
91
Value
89
Momentum
81
Accruals
69
Quality
59
Revisions
49
Size
37
Issuance
31
Growth
25

Volatility (91): The share price has been relatively steady.

Growth (25): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ZYME stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ZYME, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60Jan 26Apr 26Jul 26Oct 26ZYMEHigh $60Median $38Low $32

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
14 Buy0 Hold0 Sell
Low $32Median $38High $60

The green dot is the last close — the median target sits +50.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 9 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
29 Sept 2026CitigroupMaintainsBuy$38 → $39
17 Sept 2026Wolfe ResearchInitiatesOutperform—
17 Sept 2026Wolfe ResearchInitiatesOutperform—
3 Sept 2026JP MorganMaintainsOverweight$31 → $33
3 Sept 2026JP MorganMaintainsOverweight—
26 Aug 2026CitigroupMaintainsBuy—
26 Aug 2026CitigroupMaintainsBuy$37 → $38
26 Aug 2026CitizensReiteratesMarket Outperform$32
26 Aug 2026CitizensReiteratesMarket Outperform—
26 Aug 2026HC Wainwright & Co.MaintainsBuy—
26 Aug 2026HC Wainwright & Co.MaintainsBuy$51 → $55
10 Aug 2026B. Riley SecuritiesReiteratesBuy$40 → $44
10 Aug 2026B. Riley SecuritiesReiteratesBuy—
7 Aug 2026Truist SecuritiesMaintainsBuy—
7 Aug 2026Truist SecuritiesMaintainsBuy$31 → $32
7 Aug 2026Wells FargoMaintainsOverweight—
7 Aug 2026Wells FargoMaintainsOverweight$37 → $40
5 Aug 2026HC Wainwright & Co.MaintainsBuy—
5 Aug 2026HC Wainwright & Co.MaintainsBuy$46 → $51
7 July 2026Truist SecuritiesMaintainsBuy$28 → $31

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ZYME appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ZYME vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Zymeworks, Inc. returned +51.4% against +16.2% for the S&P 500, dividends included.

ZYME vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160180Jan 26Apr 26Jul 26Oct 26ZYMES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ZYME analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−36.2%
Analysts raising
1
Analysts cutting
2
Fundamentals

Zymeworks, Inc. (ZYME) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
3.8×

Cheaper than 67% of US stocks

Price / sales
49.6×

Cheaper than 6% of US stocks

Price / book
22.8×

Cheaper than 4% of US stocks

EV / EBITDA
−10.4×

Cheaper than 85% of US stocks

Growth & margins
Revenue growth (YoY)
−90.6%

Higher than 2% of US stocks

Earnings growth (YoY)
−90.6%

Higher than 3% of US stocks

Gross margin
—
Operating margin
−919.0%

Higher than 6% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−72.3%

Higher than 17% of US stocks

Return on assets
−24.1%

Higher than 17% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Zymeworks, Inc. (ZYME) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Zymeworks, Inc. has a market value of $1.8B and an enterprise value of $1.6B.

  • Revenue in the twelve months to 30 June 2026: $37.1M. The latest quarter shrank 90.6% year on year.

  • Net income over the same four quarters: −$150.0M, a −404.0% net margin.

  • Diluted earnings per share, trailing twelve months: $−2.02.

  • Free cash flow in the twelve months to 30 June 2026: −$120.7M.

  • Zymeworks, Inc. spent $169.8M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 72.0M.

  • Trailing P/E: 3.8×; forward P/E: 29.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Zymeworks, Inc. employs 231 people — $161K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

ZYME vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ZYMEZymeworks, Inc.$1.8B
63
URGNUroGen Pharma Ltd.$1.8B
83
NVAXNovavax, Inc.$1.8B
58
TRVITrevi Therapeutics, Inc.$1.8B
48
XNCRXencor, Inc.$1.8B
83
GENBGenerate Biomedicines, Inc.$1.8B
1
MRVIMaravai Lifesciences Holdings, Inc.$1.8B
88

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Zymeworks, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ZYME news & analysis

Zymeworks Completes Theravance Deal, Adds YUPELRI Cash Flow and Raises 2026 Outlook

MarketBeat · 2 Oct 2026positive

Zymeworks completed its acquisition of Theravance Biopharma, adding the COPD medicine YUPELRI, a research portfolio, collaboration and royalty economics, Irish tax attributes, and a commercial organization to its business. The company raised its 2026 outlook following the deal's completion.

Why it matters — Zymeworks watchers would care because the deal brings YUPELRI cash flow, a commercial organization, and improved tax attributes, along with an upwardly revised 2026 outlook.

Zymeworks Inc. (ZYME) M&A Call Transcript

Seeking Alpha · 28 Sept 2026neutral

Zymeworks Inc. held an M&A call, and Seeking Alpha published the transcript of that call. The excerpt provided contains only the transcript headline and source attribution, with no details on the content discussed.

Why it matters — A transcript of the M&A call may provide ZYME watchers with insights into the company's strategic and merger-related discussions.

Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition

GlobeNewsWire · 28 Sept 2026neutral

Zymeworks announced the final transaction details and updated 2026 financial guidance following the completion of its acquisition of Theravance Biopharma. The announcement covers the consolidated company's financial outlook and deal specifics.

Why it matters — Zymeworks investors would want to track the updated 2026 financial guidance and final deal terms as they reflect the company's financial position after integrating Theravance Biopharma.

Zymeworks Completes Acquisition of Theravance Biopharma

GlobeNewsWire · 23 Sept 2026positive

Zymeworks announced it has completed its previously announced acquisition of Theravance Biopharma, making Theravance Biopharma part of Zymeworks as of September 23, 2026. The transaction advances Zymeworks' strategy to build a diversified, revenue-generating biotechnology company combining R&D with commercial and royalty-based cash flows.

Why it matters — The completed acquisition marks a step in Zymeworks' stated strategy to diversify its revenue streams through added commercial and royalty-based cash flows alongside its biotherapeutics pipeline.

Zymeworks Inc. (ZYME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · 14 Sept 2026neutral

Zymeworks Inc. (ZYME) presented at the Morgan Stanley 24th Annual Global Healthcare Conference, and a transcript of the presentation was published. The item reports on the company's participation in the conference.

Why it matters — A ZYME watcher would care because the conference presentation offers a forum where the company can communicate its progress and outlook to an investment audience.

FAQ

Frequently asked questions about ZYME stock

What is the ZYME stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Zymeworks, Inc. have a median 12-month price target of $38, with estimates ranging from $32 to $60. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ZYME stock a buy right now?

Of the 14 analysts covering Zymeworks, Inc., 14 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Zymeworks, Inc. 63 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ZYME?

As at 8 Oct 2026, Zymeworks, Inc. ranks 63 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (91 of 100).

Will ZYME stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +50.4% from the last close, and Ticker Nerd's factor model ranks Zymeworks, Inc. 63 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ZYME stock forecast for 2030?

No analyst covering Zymeworks, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ZYME are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $32 to $60 over the next 12 months.

How has ZYME stock performed over the past year?

Zymeworks, Inc. returned +51.4% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Zymeworks, Inc. do?

Zymeworks Inc. is a biotechnology company focused on discovering, developing, and commercializing multifunctional biotherapeutics for difficult-to-treat diseases.

What is the latest news on ZYME?

The most recent item we track (MarketBeat, 2 Oct 2026): "Zymeworks Completes Theravance Deal, Adds YUPELRI Cash Flow and Raises 2026 Outlook". Zymeworks completed its acquisition of Theravance Biopharma, adding the COPD medicine YUPELRI, a research portfolio, collaboration and royalty economics, Irish tax attributes, and a commercial organization to its business. The company raised its 2026 outlook following the deal's completion.

Company

About Zymeworks, Inc.

Zymeworks Inc. is a biotechnology company focused on discovering, developing, and commercializing multifunctional biotherapeutics for difficult-to-treat diseases. Its current work centers on oncology and other serious conditions, including inflammation and autoimmune disorders, using advanced antibody-based platforms designed to create highly differentiated drug candidates. The company’s portfolio includes licensed healthcare assets as well as clinical and preclinical programs, with products and candidates such as Ziihera and pasritamig among its notable programs. Zymeworks also develops antibody-drug conjugates and multispecific therapeutics, reflecting a broader strategy of combining proprietary platforms with partnered assets to address unmet medical needs. The company plays a specialized role in the biopharmaceutical market by advancing targeted therapies that aim to improve treatment options across cancer and immunology-focused segments.

CEO Mr. Kenneth H. Galbraith C.A. · 231 employees · United States · https://www.zymeworks.com